![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Latest study shows Sanzyme Biologics's Bacillus coagulans SNZ 1969® (Weizmannia coagulans SNZ 1969), a natural spore forming probiotic strain over five decades of use and more than 30 human studies across age groups found to be effective in managing IBS symptoms.
Lead Product(s): Probiotic Strain SNZ 1969
Therapeutic Area: Gastroenterology Product Name: SNZ 1969
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
The probiotic portfolio includes Sporlac, which is the third-largest probiotics brand in India, and specialised products like Lobun used for delaying progression of chronic kidney disease and Oxalo, an alternate risk-free therapy to decalcify kidney stones.
Lead Product(s): Lacticacid Bacillus
Therapeutic Area: Gastroenterology Product Name: Sporlac
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: J.B.Chemicals & Pharmaceuticals
Deal Size: $84.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 26, 2022